Head-to-head evidence
MET-097i vs XW014
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
MET-097i
Developed by Pfizer
NCT06897202 · Phase 2 · completed
The trial randomly assigned 133 participants to MET097 or placebo and was double-blinded, with percent change in body weight as the primary clinical endpoint. However, because no primary efficacy results are available, it is not possible to determine whether the endpoint was met.
Figures from conference coverage of the ADA 2026 presentation; weight change is from baseline, not placebo-adjusted, and no significance testing was reported for the weight endpoint. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: October 2027 · NCT07400653 (registry estimate)
XW014
Developed by Sciwind Biosciences
NCT05579314 · Phase 1 · completed
This is a randomized, blinded, placebo-controlled trial, but its primary endpoints are adverse events and routine safety measurements rather than a diabetes outcome such as blood sugar control, and no results have been posted yet.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: MET-097i's landscape · XW014's landscape